CMS Expands Coverage of HYQVIA for PI Patients to In-Home Use
- By BSTQ Staff
The Centers for Medicare and Medicaid Services (CMS) has expanded coverage to include in-home use of HYQVIA (immune globulin infusion 10 percent [human] with recombinant human hyaluronidase) to treat primary immunodeficiency patients. Following HYQVIA’s U.S. Food and Drug Administration approval in 2014, CMS covered both provider facility and in-office treatment with HYQVIA. The expansion includes durable medical equipment coverage of the infusion pump required to administer the drug. “Today’s decision from CMS reinforces the value of HYQVIA and will help expand access to even more people who can benefit from the flexibility of self-administering HYQVIA in their own homes,” said Jacopo Leonardi, executive vice president and president, immunology, for Baxalta. “This coverage is a critical step forward in meeting their needs and equipping them to better manage their disease.”
